OABI

OmniAb Inc

5.11

Oct 30 • 3:59 PM ET -0.12 (-2.29%)

5.01

Aftermarket • 7:30 PM ET -0.10 (-1.96%)

Healthcare Biotechnology USA Small NASD

Today, 5:53 PMOmniAb beats Q3 revenue estimates, raises 2026 revenue and cash outlook as milestones surge and xPloration ramps

Peers: ABCL ABSI XNCR LGND GENB HYFT DNA TWST ADAG HALO

| Held by: IWM VTI VXF IWN IBB VTWO SCHA DFAS IWC FESM

Scroll to Statements

Index	RUT
Market Cap	742.94M
Enterprise Value	709.86M
Income	-44.27M
Sales	38.46M
Book/sh	1.79
Cash/sh	0.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	89
IPO	Sep 30, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	19.32
P/B	2.85
P/C	14.29
P/FCF	-
EV/EBITDA	-
EV/Sales	18.46
Quick Ratio	4.72
Current Ratio	4.80
Debt/Eq	0.07
LT Debt/Eq	0.06
Option/Short	Yes / Yes

EPS (ttm)	-0.36
EPS next Y	-0.27
EPS next Q	-0.13
EPS this Y	38.10%
EPS next Y	24.90%
EPS next 5Y	44.97%
EPS past 3/5Y	-29.62% -14.88%
Sales past 3/5Y	-31.89% -14.39%
EPS Y/Y TTM	40.54%
Sales Y/Y TTM	67.01%
EPS Q/Q	69.59%
Sales Q/Q	244.24%
Earnings	Oct 30 BMO
EPS/Sales Surpr.	5.59% 14.34%

Insider Own	18.49%
Insider Trans	0.00%
Inst Own	49.26%
Inst Trans	-4.21%
ROA	-15.11%
ROE	-16.95%
ROIC	-16.09%
Gross Margin	36.40%
Oper. Margin	-125.96%
Profit Margin	-115.12%
SMA20	6.66%
SMA50	9.80%
SMA200	89.07%
Trades

Shs Outstand	145.39M
Shs Float	118.51M
Short Float	7.21%
Short Ratio	5.16
Short Interest	8.54M
52W High	5.43 -5.89%
52W Low	1.30 293.08%
Volatility	8.83% 7.87%
ATR (14)	0.36
RSI (14)	58.66
Beta	0.61
Rel Volume	1.28
Avg Volume	1.66M
Volume	2,114,027

Perf Week	9.66%
Perf Month	2.40%
Perf Quarter	160.71%
Perf Half Y	265.00%
Perf YTD	176.22%
Perf Year	242.95%
Perf 3Y	13.81%
Perf 5Y	-48.85%
Perf 10Y	-
Recom	1.00
Target Price	8.21
Prev Close	5.23
Price	5.11
Change %	-2.29%

Consensus

Strong Buy

Avg. Price Target

$8.21

Implied Upside

+60.7%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 29, 2023	Initiated	RRBC Capital Mkts	Outperform	$6	+17.4%
Apr 21, 2023	Initiated	TThe Benchmark Company	Buy	$8	+56.6%
Apr 13, 2023	Initiated	CCraig Hallum	Buy	$10	+95.7%
Feb 22, 2023	Initiated	CCowen	Outperform	$10	+95.7%
Feb 13, 2023	Initiated	HH.C. Wainwright	Buy	$11	+115.3%
Dec 20, 2022	Initiated	TTruist	Buy	$10	+95.7%
Dec 16, 2022	Initiated	CCredit Suisse	Outperform	$13	+154.4%
Nov 29, 2022	Initiated	SSVB Leerink	Outperform	$6	+17.4%
Nov 28, 2022	Initiated	SStifel	Buy	$12	+134.8%

Today 11:01AM	OmniAb Matches On EPS, Beats On Revenue, And Lifts Its Cash Outlook As Q3 Exposes The Lumpiness Of A Milestone-Driven Model (Earnings Whispers)
07:40AM	OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights (Business Wire)
Oct-26-26 04:05PM	OmniAb to Participate in Upcoming Investor Conferences in November (Business Wire) +7.59%
Oct-22-26 08:13AM	OmniAb Faces Quieter Milestone Quarter After A Doubling Stock And Three Guidance Raises (Earnings Whispers)
Oct-14-26 04:05PM	OmniAb to Report Third Quarter 2026 Financial Results on October 30 (Business Wire)
08:00AM	Loading…
Oct-06-26 08:00AM	OmniAb Highlights Partner Pipeline, xPloration Plans and Outlook, and Introduces the OmniTides Platform at Investor & Analyst Day (Business Wire) -11.59%
Sep-14-26 08:00AM	OmniAb to Host Investor & Analyst Day on October 6, 2026 (Business Wire) +10.07%
Aug-28-26 03:00PM	VERAXA Biotech (VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology (NewMediaWire)
Aug-26-26 08:00AM	OmniAb to Participate in Upcoming Investor Conferences (Business Wire)
Aug-17-26 04:47PM	OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook (GuruFocus.com) +13.02%
07:01AM	OmniAb lifts 2026 cash outlook following licensing momentum (InvestorsHub)
06:06AM	OmniAb Raises 2026 Financial Guidance (Business Wire)
06:01AM	OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company (Business Wire)
Aug-07-26 01:06AM	OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ... (GuruFocus.com) +37.50%
Aug-06-26 02:30PM	VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies (NewMediaWire) +10.34%
09:40AM	Loading…
Aug-05-26 09:40AM	Earnings To Watch: OmniAb Inc (OABI) Q2 2026 -- GF Value Sees 54% Upside (GuruFocus.com)
Jul-27-26 03:37PM	VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration (NewMediaWire)
Jul-16-26 08:00AM	OmniAb to Report Second Quarter 2026 Financial Results on August 6 (Business Wire)
Jul-13-26 08:00AM	OmniAb Names Amechi Nwachuku Chief Operating Officer (Business Wire) -7.86%
Jul-06-26 12:00PM	The Cancer Therapy Strategy VERAXA Is Betting the Company On (Exec Edge)
May-07-26 04:05PM	OmniAb Reports First Quarter 2026 Financial Results and Business Highlights (Business Wire) +12.93%
May-06-26 09:33AM	OmniAb Inc (OABI) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-24-26 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire) -6.41%
Apr-21-26 08:00AM	OmniAb to Report First Quarter 2026 Financial Results on May 7 (Business Wire)
Mar-05-26 12:02AM	OmniAb Inc (OABI) Q4 2025 Earnings Call Highlights: Strong Partner Engagement and New ... (GuruFocus.com) +10.50%
Mar-04-26 07:57PM	OmniAb Q4 Earnings Call Highlights (MarketBeat)
05:55PM	OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (Business Wire)
Mar-03-26 07:20AM	OmniAb Inc (OABI) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-24-26 08:00AM	OmniAb to Participate at the Leerink Partners Global Healthcare Conference (Business Wire)
08:00AM	Loading…
Feb-19-26 08:00AM	OmniAb to Report Fourth Quarter 2025 Financial Results on March 4 (Business Wire)
Dec-15-25 04:05PM	Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies (Business Wire) -5.58%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire) +8.00%
Dec-04-25 04:05PM	OmniAb to Hold OmniUltra Virtual Investor Event on December 15 (Business Wire)
Nov-17-25 05:23PM	OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors (Business Wire) +5.92%
Nov-05-25 12:06AM	OmniAb Inc (OABI) Q3 2025 Earnings Call Highlights: Strong Program Momentum Amid Revenue Decline (GuruFocus.com)
Nov-04-25 06:35PM	OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Nov-03-25 08:07AM	What To Expect From OmniAb Inc (OABI) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 10:00AM	OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-16-25 08:55AM	Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
08:00AM	OmniAb to Participate in Three Investor Conferences in November (Business Wire)
Oct-14-25 08:00AM	OmniAb to Report Third Quarter 2025 Financial Results on November 4 (Business Wire)
Sep-02-25 08:00AM	OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-25-25 07:00AM	OmniAb Announces $30 Million Private Placement (Business Wire) -11.89%
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:05PM	OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Aug-05-25 10:26AM	OmniAb Inc (OABI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-16-25 08:00AM	OmniAb to Report Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
May-13-25 04:05PM	OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration Platform at the 21st Annual PEGS Boston Summit (Business Wire) +8.57%
May-09-25 08:31AM	Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) -8.28%
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:06PM	OmniAb Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:05PM	OmniAb Introduces the xPloration® Partner Access Program (Business Wire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
May-01-25 08:00AM	OmniAb to Participate in Five Upcoming Investor Conferences (Business Wire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-14-25 08:00AM	OmniAb to Report First Quarter 2025 Financial Results on May 8 (Business Wire)
Mar-18-25 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire) -20.38%
Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GUSTAFSON KURT A	Officer	Apr 07 '26	Proposed Sale	1.49	6,913	10,266		Apr 07 08:33 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '26	Option Exercise	0.00	36,459	0	4,439,736	Apr 07 08:26 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '26	Sale	1.49	19,244	28,674	4,420,492	Apr 07 08:26 PM
FOEHR MATTHEW W	Officer	Apr 07 '26	Proposed Sale	1.49	19,244	28,577		Apr 07 08:25 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '26	Option Exercise	0.00	13,542	0	268,396	Apr 07 08:25 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '26	Sale	1.49	6,913	10,300	261,483	Apr 07 08:25 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '26	Option Exercise	0.00	13,542	0	406,242	Apr 07 08:23 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '26	Sale	1.49	7,157	10,664	399,085	Apr 07 08:23 PM
Berkman Charles S	Officer	Apr 07 '26	Proposed Sale	1.49	7,157	10,628		Apr 07 08:12 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '26	Option Exercise	0.00	18,750	0	402,373	Feb 18 06:36 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '26	Sale	1.71	9,673	16,541	392,700	Feb 18 06:36 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 18 '26	Option Exercise	0.00	18,750	0	278,152	Feb 18 06:35 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 18 '26	Sale	1.71	9,301	15,905	268,851	Feb 18 06:35 PM
FOEHR MATTHEW W	President and CEO	Feb 18 '26	Sale	1.71	30,843	52,742	4,403,277	Feb 18 06:34 PM
FOEHR MATTHEW W	President and CEO	Feb 16 '26	Option Exercise	0.00	36,458	0	4,396,541	Feb 17 06:22 PM
FOEHR MATTHEW W	President and CEO	Feb 17 '26	Sale	1.70	20,754	35,282	4,375,787	Feb 17 06:22 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 16 '26	Option Exercise	0.00	13,542	0	266,230	Feb 17 06:20 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 17 '26	Sale	1.70	6,828	11,608	259,402	Feb 17 06:20 PM
Berkman Charles S	Chief Legal Officer	Feb 16 '26	Option Exercise	0.00	13,542	0	390,613	Feb 17 06:18 PM
Berkman Charles S	Chief Legal Officer	Feb 17 '26	Sale	1.70	6,990	11,883	383,623	Feb 17 06:18 PM
FOEHR MATTHEW W	Officer	Feb 17 '26	Proposed Sale	1.70	20,483	34,821		Feb 17 04:33 PM
Berkman Charles S	Officer	Feb 17 '26	Proposed Sale	1.70	6,891	11,715		Feb 17 04:29 PM
GUSTAFSON KURT A	Officer	Feb 17 '26	Proposed Sale	1.70	6,891	11,715		Feb 17 04:27 PM
Berkman Charles S	Chief Legal Officer	Dec 07 '25	Option Exercise	0.00	15,621	0	385,115	Dec 09 09:02 AM
Berkman Charles S	Chief Legal Officer	Dec 08 '25	Sale	1.96	8,044	15,766	377,071	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 07 '25	Option Exercise	0.00	46,500	0	276,610	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 08 '25	Sale	1.96	23,922	46,887	252,688	Dec 09 09:02 AM
FOEHR MATTHEW W	President and CEO	Dec 07 '25	Option Exercise	0.00	26,554	0	4,373,749	Dec 09 09:01 AM
FOEHR MATTHEW W	President and CEO	Dec 08 '25	Sale	1.96	13,666	26,785	4,360,083	Dec 09 09:01 AM
GUSTAFSON KURT A	Officer	Dec 08 '25	Proposed Sale	1.96	23,922	46,910		Dec 08 07:17 PM
FOEHR MATTHEW W	Officer	Dec 08 '25	Proposed Sale	1.96	13,666	26,798		Dec 08 07:15 PM
Berkman Charles S	Officer	Dec 08 '25	Proposed Sale	1.96	8,044	15,774		Dec 08 07:14 PM
HIGGINS JOHN L	Director	Nov 07 '25	Buy	1.38	41,038	56,632	2,929,148	Nov 10 08:30 AM
HIGGINS JOHN L	Director	Nov 06 '25	Buy	1.41	36,223	51,074	2,888,110	Nov 10 08:30 AM

OmniAb, Inc. operates as a drug discovery company. The firm focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

PresidentMr. Matthew W. Foehr

Executive VP of Finance & CFOMr. Kurt A. Gustafson

Chief Legal OfficerMr. Charles S. Berkman J.D.

Executive VP & Chief Operating OfficerMr. Amechi Nwachuku

Senior Vice President of People & TalentMs. Cia McCaffrey

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OABI

OmniAb Inc

Upgrade your Finviz experience